Spontaneous ARIA-like Events in Cerebral Amyloid Angiopathy–Related Inflammation
暂无分享,去创建一个
R. Marconi | R. Carare | G. Basso | D. Inzitari | V. Di Lazzaro | E. Scarpini | A. Charidimou | M. Caulo | R. Nitrini | F. Tagliavini | A. Cagnin | A. Padovani | M. Zedde | R. Pascarella | L. Antolini | Atsushi Shima | C. Ferrarese | M. Sessa | M. Cirillo | M. Ihara | F. Piazza | R. Valenti | M. Marcon | F. Perini | J. Vázquez-Costa | J. DiFrancesco | A. Arighi | Yuta Hagiwara | A. Giossi | A. Villarejo-Galende | G. Perini | N. Ziliotto | B. Orlandi
[1] E. Chung,et al. Moderate Aortic Stenosis in Patients With Heart Failure , 2022, Korean circulation journal.
[2] L. Ferrucci,et al. Effects of monoclonal antibodies against amyloid-β on clinical and biomarker outcomes and adverse event risks: A systematic review and meta-analysis of phase III RCTs in Alzheimer’s disease , 2021, Ageing Research Reviews.
[3] M. Mintun,et al. Donanemab in Early Alzheimer's Disease. , 2021, The New England journal of medicine.
[4] Nick C Fox,et al. Longitudinal Accumulation of Cerebral Microhemorrhages in Dominantly Inherited Alzheimer Disease , 2021, Neurology.
[5] A. Izenberg,et al. Clinical Reasoning: An 81-year-old woman with decreased consciousness and fluctuating right facial droop , 2020, Neurology.
[6] D. Holtzman,et al. Clearance of interstitial fluid (ISF) and CSF (CLIC) group—part of Vascular Professional Interest Area (PIA) , 2020, Alzheimer's & dementia.
[7] M. Andjelkovic,et al. Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer’s disease: a PET substudy interim analysis , 2019, Alzheimer's Research & Therapy.
[8] P. Nichelli,et al. A challenging diagnosis of reversible “vascular” dementia: Cerebral amyloid angiopathy-related inflammation , 2019, Journal of Neuroimmunology.
[9] S. Black,et al. Special topic section: linkages among cerebrovascular, cardiovascular, and cognitive disorders: Preventing dementia by preventing stroke: The Berlin Manifesto. , 2019, International journal of stroke : official journal of the International Stroke Society.
[10] Meagan Bailey,et al. Pearls & Oy-sters: CAA-related inflammation presents as subacute cognitive decline in a patient with Parkinson disease , 2019, Neurology.
[11] R. Sperling,et al. The Future of Anti-Amyloid Trials , 2019, The Journal of Prevention of Alzheimer's Disease.
[12] R. Carare,et al. Cerebrovascular Smooth Muscle Cells as the Drivers of Intramural Periarterial Drainage of the Brain , 2019, Front. Aging Neurosci..
[13] E. Carrera,et al. Clinical Reasoning: Rapid progression of reversible cognitive impairment in an 80-year-old man , 2018, Neurology.
[14] H. Markus,et al. Cerebral amyloid angiopathy associated with inflammation: A systematic review of clinical and imaging features and outcome. , 2018 .
[15] D. Werring,et al. Minimally symptomatic cerebral amyloid angiopathy-related inflammation: three descriptive case reports , 2018, Journal of Neurology, Neurosurgery, and Psychiatry.
[16] Nick C Fox,et al. Biomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumab , 2018, Neurology.
[17] Eric E. Smith,et al. The increasing impact of cerebral amyloid angiopathy: essential new insights for clinical practice , 2017, Journal of Neurology, Neurosurgery, and Psychiatry.
[18] Keith A. Johnson,et al. Florbetapir-PET to diagnose cerebral amyloid angiopathy , 2016, Neurology.
[19] Blaine R. Roberts,et al. The Neurobiology and Age-Related Prevalence of the ε4 Allele of Apolipoprotein E in Alzheimer’s Disease Cohorts , 2016, Journal of Molecular Neuroscience.
[20] F. Pasquier,et al. Apolipoprotein E (APOE) ε4 and episodic memory decline in Alzheimer’s disease: A review , 2016, Ageing Research Reviews.
[21] M. Frosch,et al. Validation of Clinicoradiological Criteria for the Diagnosis of Cerebral Amyloid Angiopathy-Related Inflammation. , 2016, JAMA neurology.
[22] B. Gómez-Anson,et al. Cerebrospinal Fluid Anti-Amyloid-β Autoantibodies and Amyloid PET in Cerebral Amyloid Angiopathy-Related Inflammation. , 2015, Journal of Alzheimer's disease : JAD.
[23] D. Werring,et al. White Matter Changes in Dementia: Role of Impaired Drainage of Interstitial Fluid , 2015, Brain pathology.
[24] Jaekwang Kim,et al. Apolipoprotein E in Synaptic Plasticity and Alzheimer’s Disease: Potential Cellular and Molecular Mechanisms , 2014, Molecules and cells.
[25] R. Sperling,et al. Inflammatory cerebral amyloid angiopathy and amyloid‐modifying therapies: Variations on the Same ARIA? , 2013, Annals of neurology.
[26] Antonio Colombo,et al. Anti–amyloid β autoantibodies in cerebral amyloid angiopathy–related inflammation: Implications for amyloid‐modifying therapies , 2013, Annals of neurology.
[27] Y. Hayashi,et al. Corticosteroid therapy in a patient with cerebral amyloid angiopathy-related inflammation , 2013, Journal of Neuroinflammation.
[28] Nick C Fox,et al. Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis , 2012, The Lancet Neurology.
[29] F. Barkhof,et al. Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. , 2012, Archives of neurology.
[30] B. Borroni,et al. Increased tissue factor pathway inhibitor and homocysteine in Alzheimer's disease , 2012, Neurobiology of Aging.
[31] Clifford R. Jack,et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer’s Association Research Roundtable Workgroup , 2011, Alzheimer's & Dementia.
[32] S. Leurgans,et al. Cerebral amyloid angiopathy pathology and cognitive domains in older persons , 2011, Annals of neurology.
[33] I. Appollonio,et al. Cholinesterase inhibitor use is associated with increased plasma levels of anti-Abeta 1–42 antibodies in Alzheimer's disease patients , 2010, Neuroscience Letters.
[34] B. Synek,et al. Cerebral amyloid angiopathy related inflammation: three case reports and a review , 2010 .
[35] N. Scolding,et al. Cerebral amyloid angiopathy related vasculitis: successful treatment with azathioprine , 2010, Journal of Neurology.
[36] A. Maggi,et al. Increased atherosclerosis and vascular inflammation in APP transgenic mice with apolipoprotein E deficiency. , 2010, Atherosclerosis.
[37] D. Holtzman,et al. The Role of Apolipoprotein E in Alzheimer's Disease , 2009, Neuron.
[38] Keith A. Johnson,et al. Imaging of amyloid burden and distribution in cerebral amyloid angiopathy , 2007, Annals of neurology.
[39] K. Jellinger,et al. Alzheimer disease and cerebrovascular pathology: an update , 2002, Journal of Neural Transmission.
[40] B. Winblad,et al. Amyloid-Related Imaging Abnormalities (ARIA) in Immunotherapy Trials for Alzheimer's Disease: Need for Prognostic Biomarkers? , 2016, Journal of Alzheimer's disease : JAD.
[41] R. Levy,et al. Recurrence of Cerebral Amyloid Angiopathy-Related Inflammation: A Report of Two Cases from the iCAβ International Network. , 2015, Journal of Alzheimer's disease : JAD.
[42] J. Ferro,et al. Cerebral Amyloid Angiopathy Associated with Inflammation: Report of 3 Cases and Systematic Review. , 2015, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.
[43] E. Parati,et al. Prodromal Alzheimer's disease presenting as cerebral amyloid angiopathy-related inflammation with spontaneous amyloid-related imaging abnormalities and high cerebrospinal fluid anti-Aβ autoantibodies. , 2015, Journal of Alzheimer's disease : JAD.
[44] M. Uchino,et al. Cerebral amyloid angiopathy-related inflammation presenting with steroid-responsive higher brain dysfunction: case report and review of the literature , 2011, Journal of Neuroinflammation.
[45] D. Troost,et al. OR PART OF THE FOLLOWING SOURCE ) : Type article Title Steroid responsive encephalopathy in cerebral amyloid angiopathy : a case report and review of evidence for immunosuppressive treatment , 2010 .